129792827984687500_6Chongqing Brewery produces fails the hepatitis b immunization summary report for more than 10 days, Chongqing Brewery (600,132 shares, market, news, main trading) treatment (synthetic peptides) hepatitis b vaccine clinical trial summary report finally released today. In the summary report of key clinical indicators and Unblinding data disclosed in December last year compared to no change, report findings show, The hepatitis b vaccine alone in the treatment of chronic hepatitis b without significant effect.
One of the medical professionals view, this result shows that the vaccine had failed, the project continued follow-up studies are less likely. It is reported that clinical trials of drugs used in this report as a separate group summary report and summary report of the combined group has yet to come. Chongqing brewery said the company will doAlone is set to communicate project-related matters with interested parties and experts, you alone is the group project follow-up study to evaluate the continued, and at the same time it is a combined group of projects in research and evaluation. Company also said treatment (synthetic peptide) is conducting follow-up studies of hepatitis b vaccine or go ahead there are significant uncertainties and risks.Notice disclosure report also shows that placebo group 900ug group 600ug group, hepatitis b vaccine and hepatitis b vaccine conversion rate, 28.2%
tera gold, and 29.1% respectively, and Unblinding data disclosed in December last year. Conversion rates are still lower than the 600ug group 900ug Group's conversion rate, meaning that the case of hepatitis b vaccine doses to increase, The effect is not ideal. Wrote in the conclusions of the report, treatment (synthetic peptides) alone in the treatment of chronic hepatitis b hepatitis b vaccines, therapeutic doses from 600ug up to 900ug at a time when every time, in key clinical indicators and indicators of secondary effects, no significant effect. In addition, security appears in the results
tera power leveling, 900ug groups of subjects with chronicHepatitis exacerbation of severe adverse events, but better overall security. Report data also show that only the 28th week observation time point, subject serum conversion rate differences are statistically significant.
28th week drug response rate for the 900ug group 30%, placebo response rate of 8.8%. Or because of expectations of a reversal in the summary report, after Chongqing beerWine after the share price fell to $ 20.16 in the bottom, once reached $ 40.88.
The unit yesterday's closing price of $ 29.97, the turnover reached $ 720 million. Securities online Gold in times of declared: Gold-line reproduced above, does not indicate that confirm the description
tera power leveling, for investors ' reference only and does not constitute investment advice. Investor operations accordingly, at your own risk.
The other news around this topic
:
留言列表
留言列表
